Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease

Exclusion Criteria22

• Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:
• Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months
• Previously received coronary artery bypass grafting
• Stroke occurred within the previous 3 months
• Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction \< 35%
• Revascularization or surgical procedures are planned within the next 3 months
• Progressive neuromuscular disease, or creatine kinase (CK) levels \> 3 times the normal upper limit (ULN)
• Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases
• Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study
• History of hereditary dyslipidemia such as familial hypercholesterolemia
• There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan
• History of symptomatic non-traumatic cerebral hemorrhage at any time in the past
• History of gastrointestinal bleeding or major surgery within the past 6 months
• Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month
• There were clear adverse reactions to the main components of Xuesaitong in the past
• Active liver disease, or alanine aminotransferase (ALT) levels \> 3 times the upper limit of normal (ULN)
• Chronic kidney disease, or estimated glomerular filtration rate (eGFR) \<60ml/ (min×1.73m2)
• Pregnancy or planned pregnancy, or breastfeeding
• Malignant tumors, or other serious diseases with an estimated survival of less than 1 year
• Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation
• Have participated in or are participating in other clinical trials within the last 1 month
• Poor adherence to follow-up or medication is known